Monday, 20 May 2019

You are here

Intraarticular Trans-Capsaicin Effective in Knee OA

A novel study has shown that intraarticular therapy with high‐purity synthetic trans‐capsaicin (CNTX‐4975) for chronic knee osteoarthritis (KOA) was associated with significant relief of knee pain.

The TRIUMPH study was a double‐blind, phase 2 study in adults (45–80 years) with stable knee osteoarthritis. Patients were given an intra‐articular injection of placebo, CNTX‐4975 0.5 mg, or CNTX‐4975 1.0 mg. The primary efficacy endpoint was area under the curve (AUC) for change in the WOMAC pain with walking scores at week 12.

A total of 172 subjects were enrolled and at week 12, greater decreases in WOMAC pain scores were observed with CNTX‐4975 versus placebo.

  • CNTX-4975 0.5 mg: LSMD, −0.79; P = 0.0740;
  • CNTX-4975 1.0 mg: LSMD, −1.6; P < 0.0001).  Efficacy continued till week 24 in the 1.0‐mg group (LSMD, −1.4; P = 0.0002.

Adverse events were similar in the placebo and 1.0‐mg groups.

Knee pain from KOA may be effectively and safely managed with this new investigational compound, CNTX‐4975 and is thought to be mediated by sustained desensitization of nociceptors (pain sensory fibers).


The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

CDC: One in Four US Adults have Arthritis

MMWR reports that in 2017, one in four US adults have arthritis (range from 22.8% to 34.6%), with higher rates in Appalachia and Lower Mississippi Valley regions. Of those with arthritis, 31% reported to have "severe arthritis".

More Studies Needed to Optimize the Use of Osteoporosis Drugs

The Annals of Internal Medicine reports a metanalysis done to examine the optimal length of long-term osteoporosis drug treatment (ODT) and whether harms are associated with long-term ODT and while the ODT benefits are clear, the risk of rare harms and need for drug holidays is less certain. 

NIH Workshop on Unmet Needs in Osteoporosis

In October 2018, the National Institutes of Health (NIH) convened a workshop to address the "Appropriate Use of Drug Therapies for Osteoporotic Fracture Prevention"

Smoking Not Protective Against Knee OA

Researchers found no protective effect of smoking against knee osteoarthritis (OA), according to a new longitudinal cohort study of 620 individuals with meniscal tears treated at five sites in Denmark. An inverse association between OA and smoking had been suggested by several previous studies and a recent meta-analysis.  

FDA Approves Romosuzumab (Evenity) for High Risk Osteoporosis

The US Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of osteoporotic fracture, including those with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intolerant to other osteoporosis therapies.